FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 697 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Newest Gerber Baby is Child of Breast Cancer Survivor June 29, 2021 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL June 8, 2023 New on NCI’s Websites for January 2020 January 2, 2020 Load more HOT NEWS Study Identifies Hundreds of Potential Targets for Cancer Drugs Tailored Psychotherapy Eases Depression in People with Advanced Cancer Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... FDA Approves Avapritinib for Advanced Systemic Mastocytosis
